FACT-Prostate: Functional Assessment of Cancer Therapy—Prostate
Functional Assessment of Cancer Therapy—Prostate · Also known as: FACT-P
The FACT-Prostate (FACT-P) is a disease-specific quality-of-life instrument for men with prostate cancer, combining the 27-item FACT-G core with a 12-item prostate-specific subscale addressing urinary, sexual, and bowel function concerns. Developed and validated by Esper et al. in 1997, it is a standard outcome measure in prostate cancer clinical trials and clinical practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
FACT-Prostate is indicated for men with prostate cancer (any Gleason score, any stage) undergoing active surveillance, radiation therapy, surgery (prostatectomy), hormone therapy, or chemotherapy. Primary use is clinical trials assessing treatment efficacy and patient-reported outcomes; secondary use in oncology clinic monitoring (baseline, q3–6 months during active treatment, post-treatment follow-up). NOT suitable for screening or diagnosis. Particularly valuable when treatment decisions involve functional trade-offs (e.g., radiation vs. surgery impact on continence and erectile function; hormone therapy toxicity; chemotherapy burden in advanced disease).
Strengths & limitations
- Prostate-specific subscale directly measures urinary, sexual, and bowel function—critical QoL domains for men with prostate cancer and its treatments.
- Extensive validation in large, diverse prostate cancer populations (low-risk through metastatic disease); robust psychometric properties across treatment modalities.
- Public domain, no licensing cost; freely available in multiple languages and modalities (paper, electronic, online).
- Widely used in major prostate cancer trials (SWOG, ECOG, NCI cooperative groups) and supportive of FDA submissions; high clinical credibility.
- Dual-layer design (FACT-G core + PCS) allows separate assessment of general cancer vs. prostate-specific burden; enables comparative analysis and targeted intervention planning.
- PCS subscale (12 items) may lack detail for highly specific dysfunction phenotyping (e.g., subtle erectile dysfunction severity, urgency vs. incontinence differentiation).
- FACT-G core assumes general cancer relevance; some items may be less salient for early-stage, low-risk prostate cancer patients.
- Sexual function items assume heterosexual partnered activity; limited applicability to single or same-sex partnered men without additional psychometric validation.
- Ceiling effects reported in early-stage post-surveillance populations; may not detect minor QoL variations.
Frequently asked
Can FACT-P be used in men on active surveillance for low-risk prostate cancer?
Yes. FACT-P is validated across prostate cancer risk strata and treatment modalities, including active surveillance. Active surveillance patients typically have higher (better) FACT-P scores than treatment-group patients, reflecting lower treatment toxicity. Longitudinal FACT-P tracking can assess anxiety, functional impact of surveillance, and any QoL changes if treatment becomes necessary.
How does FACT-P differ from the UCLA Prostate Cancer Index (UCLA PCI)?
FACT-P (39 items: 27 FACT-G + 12 PCS) combines general cancer QoL with prostate-specific domains and has a broader psychosocial emphasis. UCLA PCI (short form: 15 items) is purely prostate-specific, focusing narrowly on urinary, bowel, and sexual function; it does not include general cancer or emotional well-being. FACT-P better suited for comprehensive QoL trials; UCLA PCI optimal for functional assessment only. Both are valid; choice depends on research question.
What is the MCID for FACT-P, and how is it applied in clinical practice?
MCID for FACT-P total is approximately 10–12 points; for PCS subscale, 4–6 points. These thresholds represent the smallest change a patient would perceive as clinically meaningful. In trials, MCID helps determine whether statistically significant differences are clinically important. In clinic, serial FACT-P changes (baseline to follow-up) are more informative than absolute scores; improvement or deterioration of ≥MCID suggests meaningful change warrant clinical action (e.g., initiating erectile dysfunction therapy).
Is FACT-P appropriate for men with metastatic prostate cancer on chemotherapy?
Yes. FACT-P is validated in all prostate cancer stages, including metastatic castration-resistant prostate cancer (mCRPC) on taxane chemotherapy. Metastatic patients typically have lower baseline FACT-P scores reflecting higher disease burden and treatment toxicity. Interpretation should account for disease stage; QoL expectations and clinical meaning of FACT-P changes differ between curative-intent and palliative-intent cohorts.
How are sexual function items scored in FACT-P, and what if a man has no sexual partner?
PCS items include sexual function items assuming partnered, heterosexual activity. Men without partners or with same-sex partners may have difficulty answering these items consistently. Per FACT scoring guidelines, if >50% of PCS items are answered, subscale scoring proceeds with mean imputation for missing items. Consider supplementing with single-item sexual satisfaction questions or open-ended discussion if detailed sexual health assessment is needed beyond FACT-P.
Is FACT-P public domain, and how is it accessed?
Yes, FACT-P is public domain (free, no licensing fees). Official versions and validated translations in 25+ languages are available via FACIT.org (www.facit.org) and the developers. Always use official versions to preserve psychometric properties; modified or informally translated versions may not be valid.
Sources
- Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology, 50(6), 920–928. DOI: 10.1016/s0090-4295(97)00459-7 ↗
- Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 11(3), 570–579. DOI: 10.1200/JCO.1993.11.3.570 ↗
How to cite this page
ScholarGate. (2026, June 3). Functional Assessment of Cancer Therapy—Prostate. ScholarGate. https://scholargate.app/en/oncology/fact-prostate
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cancer Worry ScaleOncology↔ compare
- FACT-ColorectalOncology↔ compare
- FACT-LungOncology↔ compare
- FACT-OvarianOncology↔ compare
- UCLA Prostate Cancer IndexOncology↔ compare